An accomplished sales executive, Kevin Lilly formerly served as the senior vice president of sales at MiMedx, a Georgia-based biopharmaceutical firm that devises treatment solutions for advanced wound care. Through endeavors rooted in cross-functionality and talent development, Kevin Lilly built up and led a sales team that increased sales and helped to propel the company’s growth. Subsequently, MiMedx earned a place on Fortune Magazine’s 2017 list of the 100 Fastest-Growing Companies.
Fortune’s list of the Fastest-Growing Companies recognizes domestic and foreign companies that outperform others in revenue and earnings per share (EPS) growth rates and increased annualized total returns over the course of a three-year period. The magazine’s ranking process evaluates only those companies that meet or exceed specific benchmarks in these areas, in addition to fulfilling a series of preliminary qualifications. The criteria include participation in a major US Stock Exchange, continuous trading activity, and minimum figures for revenue, net income, stock price, and market capitalization.
For its 2017 list of the Fastest-Growing Companies, Fortune restricted consideration to enterprises that posted EPS and revenue annualized growth rates of 15 percent or higher over the course of a three-year timeframe that ended on April 30, 2017. Moreover, it set revenue and net income thresholds at no less than $50 million and $10 million, respectively, for the four quarters that concluded on or prior to that date.
MiMedx secured the fifth spot on the top 100 list with a three-year annualized total return rate of 28 percent. Additionally, it ranked seventh for three-year annual growth rate (AGR) in revenue and 10th for three-year AGR in EPS with 58 percent and 88 percent, respectively. In a statement at the time, the company’s CEO and chairman described the achievement as a tribute to its employees’ work and its products’ healing capabilities.
